Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: Effect on survival in patients with septic shock*Ángel Crespo López, Robert F. Grover, Angela McLuckie et al.|Critical Care Medicine|2004Cited by 921
Recombinant human platelet-activating factor acetylhydrolase for treatment of severe sepsis: Results of a phase III, multicenter, randomized, double-blind, placebo-controlled, clinical trial*Steven M. Opal, John P. Pribble, Pierre‐François Laterre et al.|Critical Care Medicine|2004Cited by 145